KFU. Card publication. Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives, in vitro Study

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

ANTICANCER POTENTIAL OF PYRIDOXINE-BASED DOXORUBICIN DERIVATIVES, IN VITRO STUDY

Form of presentation

Articles in international journals and collections

Year of publication

2024

��

��

Authors, employees of KFU

Bondar Oksana Viktorovna, author

Gnezdilov Oleg Ivanovich, author

Pavelev Roman Sergeevich, author

Pugachev Mikhail Vladimirovich, author

Shtyrlin Yuriy Grigorevich, author

Authors, postgraduates KFU

Kadyrova Aysylu Suleymanovna, postgraduate kfu

Karut Rauda , postgraduate kfu

Authors, students KFU

Alrkhmun Salekh , author

Mokhammad Taraa , author

Bibliographic description in the original language

Karwt R. Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives, in vitro Study / R. Karwt, O.V. Bondar, M.V. Pugachev, T. Mohammad, R.S. Pavelyev, S. Al-rhmoun, O.I. Gnezdilov, Y.G. Shtyrlin / Life. 2024; 14(3):282. PMID: 38541608 PMCID: PMC10970924 DOI: 10.3390/life14030282

Annotation

Doxorubicin (DOX) is a prevalent anticancer agent; however, it is unfortunately characterized by high cardiotoxicity, myelosuppression, and multiple other side effects. To overcome DOX limitations, two novel pyridoxine-derived doxorubicin derivatives were synthesized (DOX-1 and DOX-2). In the present study, their antitumor activity and mechanism of action were investigated. Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin molecule via a C3 linker, revealed higher selectivity against specific cancer cell types compared to doxorubicin and a promising safety profile for conditionally normal cells. However, the compound with a C1 linker (DOX-1) was not characterized by selectivity of antitumor action. It was revealed that DOX-2 obstructs cell cycle progression, induces apoptosis via the mitochondrial pathway without the development of necrosis, and showcases antioxidant capabilities, underlining its cell-regulatory roles. In contrast to doxorubicin's DNA-centric mechanism, DOX-2 does not interact with nuclear DNA. Given these findings, DOX-2 presents a new promising direction in cancer therapeutics, which is deserving of further in vivo exploration.

Keywords

doxorubicin; anticancer agents; doxorubicin derivatives; pyridoxine; vitamin B6; apoptosis induction; DNA intercalation; cell-cycle arrest; antioxidants

The name of the journal

Life

URL

https://www.mdpi.com/2075-1729/14/3/282

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=302492&p_lang=2

Resource files

File name	Size (MB)	Format
Anticancer_Potential_of_Pyridoxine_Based_Doxorubicin_Derivatives__An_In_Vitro_Study.pdf	5,80	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Bondar Oksana Viktorovna	ru_RU
dc.contributor.author	Gnezdilov Oleg Ivanovich	ru_RU
dc.contributor.author	Pavelev Roman Sergeevich	ru_RU
dc.contributor.author	Pugachev Mikhail Vladimirovich	ru_RU
dc.contributor.author	Shtyrlin Yuriy Grigorevich	ru_RU
dc.contributor.author	Alrkhmun Salekh	ru_RU
dc.contributor.author	Mokhammad Taraa	ru_RU
dc.contributor.author	Kadyrova Aysylu Suleymanovna	ru_RU
dc.contributor.author	Karut Rauda	ru_RU
dc.date.accessioned	2024-01-01T00:00:00Z	ru_RU
dc.date.available	2024-01-01T00:00:00Z	ru_RU
dc.date.issued	2024	ru_RU
dc.identifier.citation	Karwt R. Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives, in vitro Study / R. Karwt, O.V. Bondar, M.V. Pugachev, T. Mohammad, R.S. Pavelyev, S. Al-rhmoun, O.I. Gnezdilov, Y.G. Shtyrlin / Life. 2024; 14(3):282. PMID: 38541608 PMCID: PMC10970924 DOI: 10.3390/life14030282	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=302492&p_lang=2	ru_RU
dc.description.abstract	Life	ru_RU
dc.description.abstract	Doxorubicin (DOX) is a prevalent anticancer agent; however, it is unfortunately characterized by high cardiotoxicity, myelosuppression, and multiple other side effects. To overcome DOX limitations, two novel pyridoxine-derived doxorubicin derivatives were synthesized (DOX-1 and DOX-2). In the present study, their antitumor activity and mechanism of action were investigated. Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin molecule via a C3 linker, revealed higher selectivity against specific cancer cell types compared to doxorubicin and a promising safety profile for conditionally normal cells. However, the compound with a C1 linker (DOX-1) was not characterized by selectivity of antitumor action. It was revealed that DOX-2 obstructs cell cycle progression, induces apoptosis via the mitochondrial pathway without the development of necrosis, and showcases antioxidant capabilities, underlining its cell-regulatory roles. In contrast to doxorubicin's DNA-centric mechanism, DOX-2 does not interact with nuclear DNA. Given these findings, DOX-2 presents a new promising direction in cancer therapeutics, which is deserving of further in vivo exploration.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject		ru_RU
dc.title	Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives, in vitro Study	ru_RU
dc.type	Articles in international journals and collections	ru_RU